DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for acute disseminated encephalomyelitis — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAcute disseminated encephalomyelitis maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for acute disseminated encephalomyelitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Acute disseminated encephalomyelitis is a diagnosis that is frequently missed or delayed. A 1997 report of three patients describes how delay in diagnosis in the first case was associated with severe sequelae, while early diagnosis and institution of corticosteroid therapy, facilitated by early MRI, was associated with a better outcome in the other two. The authors stress that MRI should be carried out early once the diagnosis is entertained. A 2003 case report notes the difficulties in establishing a diagnosis and attempts to raise awareness among general physicians, who are most likely to see such acute neurological presentations.
A 2022 case report describes a 40-year-old woman with hypertension who presented with progressive ascending paralysis. MRI showed swelling with altered signal in the visual cervical cord, medulla, and a juxtacortical lesion in the right temporal lobe. CSF testing did not identify a direct cerebral infection. High-dose steroids followed by a course of IVIG was administered but with no significant response; the case was fatal. The authors note that in pandemic times, patients presenting with altered mentation and polyfocal neurological deficits and a background of recent COVID-19 infection or SARS-CoV-2 vaccination should be considered likely to have ADEM.
No controlled trials of any drug for ADEM are reported in these abstracts. The evidence consists of case reports and case series. What is missing is any randomised trial design, any systematic patient stratification, and any funding for prospective studies that could establish whether early corticosteroid therapy or any other intervention reliably alters outcomes.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
International Journal of Clinical Practice · 2003 · 14 citations · open access
ACUTE DISSEMINATED ENCEPHALOMYELITIS: A RIDDLE WRAPPED IN A MYSTERY INSIDE AN ENIGMA
AbstractThe difficulties in establishing a diagnosis of acute disseminated encephalomyelitis (ADEM) are illustrated in this case report, which attempts to raise awareness of the condition among general physicians, since they are the practitioners most likely to see such acute neurological presentations. Clinical and investigative features which raise the index of suspicion for the diagnosis of ADEM are outlined.
European Journal of Neurology · 1997 · 8 citations
Acute disseminated encephalomyelitis: the importance of early magnetic resonance imaging
AbstractThe diagnosis of acute disseminated encephalomyelitis (ADEM) is frequently missed or delayed with consequent delay in instituting therapy in the crucial phase of the illness. The role of MRI in the diagnosis of ADEM is well established, however, the value of its early utilization of treatment on the outcome of patients has not been adequately stressed. Three patients with ADEM are described. Delay in the diagnosis of the first was associated with severe sequelae, while in the other two early diagnosis and institution of corticosteroid therapy which was facilitated by MRI, was associated with a better outcome. MRI should be carried out early once the diagosis of ADEM is entertained.
Indian Journal of Critical Care Medicine · 2022 · 4 citations · open access
A Fatal Case of Acute Disseminated Encephalomyelitis: A Diagnosis to Ponder in Pandemic
AbstractA 40-year-old woman known hypertensive presented with progressive ascending paralysis. MRI T2W and FLAIR screening of the brain demonstrated swelling with altered signal in the visual cervical cord, medulla, and another juxtacortical lesion in the right temporal lobe with possibility of a demyelinating etiology. CSF testing did not identify a direct cerebral infection. High-dose steroids followed by a course of IVIG was administered but with no significant response. In these pandemic times, the patients who present with altered mentation and polyfocal neurological deficits and background history of recent COVID-19 infection or recipient of SARS-CoV-2 vaccine the diagnosis of acute disseminated encephalomyelitis (ADEM) should be considered likely. How to cite this article: Kumar A, Sabharwal P, Gupta P, Singh VK, Rao BK. A Fatal Case of Acute Disseminated Encephalomyelitis: A Diagnosis to Ponder in Pandemic. Indian J Crit Care Med 2022;26(4):518-520.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
